SonaCare Medical Announces Strategic Partnership with MIM®, a World Leader in Medical Imaging Software

Share Article

“A fast and accurate fusion is the key to being able to use disease-based information from a diagnostic MRI to drive a focused ultrasound ablation”

Sonablate trans-rectal HIFU probe
"We are delighted to be able to add [MIM's] premier technology to our ablation platform..." Dr. Mark Carol, CEO

SonaCare Medical, the leading developer and manufacturer of High Intensity Focused Ultrasound (HIFU) Technologies, announces today the execution of a groundbreaking licensing agreement with MIM®, a world leader in the development and deployment of medical imaging and analysis software applications.

SonaCare Medical and MIM® have worked together over the past nine months to develop cross system compatibility and deployment of the MIM Symphony™ fusion technology on the Sonablate prostate tissue ablation platform. This technology development allows annotated MRI data, generated by MIM Symphony, to be fused with intraoperative ultrasound images generated at the time of ablation. Incorporating this data into the ablation plan helps improve the targeting of regions of interest within the prostate gland during ablation.

“A fast and accurate fusion is the key to being able to use disease-based information from a diagnostic MRI to drive a focused ultrasound ablation. MIM has been a leader across many disciplines in the field of image fusion. We are delighted to be able to add their premier technology to our ablation platform, allowing users of the MIM Symphony Biopsy platform to integrate their work seamlessly into a Sonablation of prostate tissue,” comments Dr. Mark Carol, CEO of SonaCare Medical.

The integration of MIM Symphony with Sonablate was first used on a patient in early March by Dr. Richard Hindley of Nuada Group, and has been well received by the urologists who have been using the program at Nuada treatment centers since then. The software will be available for viewing at both the SonaCare (#4547) and MIM (#5313) booths at the Annual meeting of the American Urological Association (AUA) in San Diego May 6th – May 10th.

Sonablate® is the first device to receive regulatory authorization from the FDA for the focused ultrasound ablation of prostate tissue. Since its introduction over 15 years ago, Sonablate® technology has been used around the world on 15,000 patients in over 30 countries, including approximately 4,000 U.S. men who have had this procedure performed outside the U.S.

About SonaCare Medical, LLC
SonaCare Medical is a world leader in minimally invasive focused ultrasound (HIFU) technologies. SonaCare Medical is committed to developing focused ultrasound related technologies that support precise and innovative procedures for the treatment of a range of medical conditions. SonaCare Medical, with its subsidiary Focus Surgery, Inc., designs and manufactures medical devices, including the following: Sonablate®, which has 510(K) clearance in the U.S. under a De Novo regulatory classification; Sonablate® 500, which has CE Marking and has obtained regulatory authorization in more than 49 countries outside the U.S.; Sonatherm® laparoscopic HIFU surgical ablation system, which has 510(K) clearance in the U.S., has CE Marking and has obtained regulatory authorization in more than 30 countries outside the U.S.

For additional information, visit


SonaCare Medical, LLC
Erica Griffith (704) 936-1834, EricaGriffith(at)SonaCareMedical(dot)com

Forward Looking Statements.
The Company's forward-looking statements are based on management's current expectations and assumptions regarding the Company's business and performance, the economy and other future conditions and forecasts of future events, circumstances and results. As with any projection or forecast, forward-looking statements are inherently susceptible to uncertainty and changes in circumstances. The Company's actual results may vary materially from those expressed or implied in its forward-looking statements. Any forward-looking statement made by the Company speaks only as of the date on which it is made. The Company is under no obligation to, and expressly disclaims any obligation to, update or alter its forward-looking statements, whether as a result of new information, subsequent events or other factors.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Erica Griffith
Follow >
Visit website